Supernus Pharmaceuticals, Inc. (SUPN) Stock Price

SUPNStock

$37.88−23.87%52W

Market Cap$2.21B

P/E43.28x

PEG Ratio—

Div yield—

Beta0.54

SUPN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-34.31%

Price vs S&P 500 (4W)-10.13%

VGM Score42.85

P/E Ratio (Annual)43.28x

P/CF (Annual)46.60x

Book Value / Share (Quarterly)$17.73

P/TBV (Annual)5.79x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)2.52%

Cash Flow / Share (Quarterly)$0.32

Price vs S&P 500 (YTD)-35.71%

Gross Margin (TTM)88.30%

Net Profit Margin (TTM)-13.23%

EPS (TTM)$-1.91

10-Day Avg Trading Volume0.94M

EPS Excl Extra (TTM)$-1.91

Revenue Growth (5Y)6.68%

EPS (Annual)$-0.68

ROI (Annual)-3.63%

Gross Margin (Annual)89.89%

Net Profit Margin (5Y Avg)4.87%

Cash / Share (Quarterly)$6.40

Revenue Growth QoQ (YoY)32.40%

EPS Growth (5Y)-8.89%

P/E Normalized (Annual)43.28x

ROA (Last FY)-2.65%

Revenue Growth TTM (YoY)24.85%

EBITD / Share (TTM)$-0.53

ROE (5Y Avg)3.41%

Operating Margin (TTM)-15.71%

Cash Flow / Share (Annual)$0.80

P/B Ratio2.14x

P/B Ratio (Quarterly)2.62x

Net Income / Employee (Annual)$-49,600

EV / Revenue (TTM)2.44x

Net Interest Coverage (TTM)9.04x

ROA (TTM)-7.58%

EV / EBITDA (TTM)57.95x

EPS Incl Extra (Annual)$-0.68

Current Ratio (Annual)1.90x

Quick Ratio (Quarterly)1.68x

3-Month Avg Trading Volume0.82M

52-Week Price Return-23.87%

EV / Free Cash Flow (Annual)44.04x

Revenue / Employee (TTM)$1,067,400

Tangible BV / Share (Quarterly)$9.66

P/S Ratio (Annual)3.07x

Asset Turnover (Annual)0.49x

52-Week High$59.68

Operating Margin (5Y Avg)4.91%

EPS Excl Extra (Annual)$-0.68

CapEx CAGR (5Y)-17.02%

Tangible BV CAGR (5Y)5.28%

26-Week Price Return-24.41%

Quick Ratio (Annual)1.58x

13-Week Price Return-21.15%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)2.08x

Enterprise Value$2.03B

Revenue / Share Growth (5Y)5.62%

Asset Turnover (TTM)0.57x

Book Value / Share Growth (5Y)5.59%

Revenue / Employee (Annual)$924,100

Inventory Turnover (Annual)1.06x

Pretax Margin (Annual)-6.82%

Cash / Share (Annual)$5.37

3-Month Return Std Dev34.88%

Gross Margin (5Y Avg)87.93%

Net Income / Employee (TTM)$-141,200

EBITDA CAGR (5Y)-32.18%

EBITDA Interim CAGR (5Y)-2.05%

ROE (Last FY)-3.63%

Net Interest Coverage (Annual)8.96x

EPS Basic Excl Extra (Annual)$-0.68

P/FCF (TTM)15.31x

Receivables Turnover (TTM)4.71x

EV / Free Cash Flow (TTM)107.82x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.91

Receivables Turnover (Annual)4.36x

ROI (TTM)-10.42%

P/S Ratio (TTM)2.66x

Pretax Margin (5Y Avg)6.03%

Revenue / Share (Annual)$12.74

Tangible BV / Share (Annual)$8.57

Forward P/E11.59x

Free OCF CAGR (5Y)-19.37%

Price vs S&P 500 (52W)-39.41%

Year-to-Date Return-23.78%

5-Day Price Return-11.52%

EPS Normalized (Annual)$-0.68

ROA (5Y Avg)1.92%

Net Profit Margin (Annual)-5.36%

Month-to-Date Return-11.99%

Cash Flow / Share (TTM)$1.89

EBITD / Share (Annual)$0.48

EPS Growth (3Y)10.38%

Operating Margin (Annual)-8.66%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)110.77x

ROI (5Y Avg)2.56%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.91

P/TBV (Quarterly)4.81x

P/B Ratio (Annual)2.68x

Inventory Turnover (TTM)1.52x

Pretax Margin (TTM)-14.87%

Book Value / Share (Annual)$18.48

Price vs S&P 500 (13W)-23.83%

Net Margin Growth (5Y)-17.27%

Beta0.54x

P/FCF (Annual)47.95x

Revenue / Share (TTM)$14.30

ROE (TTM)-10.42%

52-Week Low$37.54

vGradeC

gGradeD

mGradeC

vgmGradeC

SUPN Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 3, 2026	$0.51	$0.53	+4.10%(+$0.02)
Q1 2026	May 5, 2026	$0.28	$0.21	-24.51%(-$0.07)
Q4 2025	Feb 24, 2026	$0.28	$0.88	+215.04%(+$0.60)
Q3 2025	Nov 4, 2025	$0.82	$0.61	-25.89%(-$0.21)
Q2 2025	Aug 5, 2025	$0.47	$0.91	+94.77%(+$0.44)

SUPN Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.17

4.09

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
SUPNSupernus Pharmaceuticals, Inc.	C	D	C	2.7x	24.9%	88.3%	-8.9%	$37.88
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing treatments for central nervous system disorders, including neurological and psychiatric conditions. Its portfolio of eight marketed products addresses key indications such as epilepsy, migraine, ADHD, Parkinson's disease complications, and dystonia. The company serves underserved patient populations within the neuroscience space.

SUPN Next Earnings Report

Report dateNov 3, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate$0.56

Revenue estimate$221.06M

Also reporting on Nov 3, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

Companies in Related Industries

NGVTIngevity CorporationChemicals
ADMAADMA Biologics, Inc.Biological Products
IOSPInnospec Inc.Chemicals
ROGRogers CorporationPlastics & Resins
CLDXCelldex Therapeutics, IncIn Vitro Diagnostics
VCELVericel CorporationBiological Products
BCRXBioCryst Pharmaceuticals IncBiological Products
MTXMinerals Technologies IncIndustrial Chemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.1

Buy

Consensus rating

52-Week Range

Low$37.54

High$59.68